It has been great to see Marks & Clerk featured in The Guardian’s coverage of the launch of Novo Nordisk’s oral weight-loss treatment, Wegovy, as the highly anticipated drug became available through UK high-street and online pharmacies. The story was subsequently picked up by a further 11 outlets across regional, national and international media, highlighting the significant public and commercial interest surrounding the latest generation of GLP-1 medicines.
As demand for these treatments continues to grow, so too do the intellectual property (IP) and brand protection challenges facing pharmaceutical companies. In the coverage, Megan Rannard warned of the increasing prevalence of websites falsely presenting themselves as legitimate online pharmacies, often offering medicines at suspiciously low prices. Such sites can expose consumers to counterfeit pharmaceuticals, fraud and phishing scams, creating both public health and brand protection concerns.
The story highlights the crucial role IP plays beyond protecting innovation itself. For pharmaceutical companies, trade marks and related enforcement strategies are key tools in combating counterfeit products, protecting brand reputation and helping patients identify legitimate sources of treatment. As the market for weight-loss medicines expands rapidly, robust IP protection remains an essential part of safeguarding both innovation and consumer trust.
Megan's comments also featured across: AOL, Streamline, the International Business Times in Singapore, Europe Says, INKL, the Exec Review, Yorkshire Live, Leeds Live, the Birmingham Mail, Agetech World and Yahoo News.
Subscribe to receive more articles like this here.
